Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$5.35
+8.1%
$5.30
$1.67
$7.29
$524.23M0.944.96 million shs6.03 million shs
Jushi Holdings Inc. stock logo
JUSHF
Jushi
$0.67
+1.6%
$0.47
$0.22
$0.98
$132.65M-0.98724,852 shs105,591 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$18.71
+1.7%
$18.21
$13.30
$25.00
$458.51M1.122,914 shs1,806 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.93
+4.8%
$5.74
$2.41
$10.07
$461.76M2.441.16 million shs794,407 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.00%+9.18%-3.60%+42.67%+184.57%
Jushi Holdings Inc. stock logo
JUSHF
Jushi
0.00%+14.62%+43.58%+117.55%+14.87%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%-0.69%-0.72%+2.80%-13.19%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
0.00%-2.95%-11.23%+111.03%-40.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.5258 of 5 stars
3.61.00.00.03.31.70.6
Jushi Holdings Inc. stock logo
JUSHF
Jushi
1.8084 of 5 stars
0.05.00.00.03.01.70.6
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
2.8161 of 5 stars
3.85.00.00.02.80.00.0
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.4075 of 5 stars
4.62.00.00.02.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.17
Buy$23.25334.58% Upside
Jushi Holdings Inc. stock logo
JUSHF
Jushi
1.00
SellN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00140.51% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.00152.95% Upside

Current Analyst Ratings Breakdown

Latest JUSHF, ATYR, PRTC, and SLDB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $17.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $13.00
8/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $14.00
7/21/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$16.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/20/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
6/4/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$230K2,279.33N/AN/A$0.76 per share7.04
Jushi Holdings Inc. stock logo
JUSHF
Jushi
$257.52M0.52N/AN/A($0.40) per share-1.69
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.32M104.64$2.35 per share7.97$17.04 per share1.10
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M57.08N/AN/A$3.32 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)
Jushi Holdings Inc. stock logo
JUSHF
Jushi
-$48.78M-$0.29N/AN/AN/A-22.56%N/A-13.23%11/6/2025 (Estimated)
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$27.78MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)

Latest JUSHF, ATYR, PRTC, and SLDB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51-$0.42+$0.09-$0.42N/AN/A
8/7/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18-$0.22-$0.04-$0.22N/AN/A
8/5/2025Q2 2025
Jushi Holdings Inc. stock logo
JUSHF
Jushi
-$0.06-$0.06N/A-$0.06$64.67 million$65.05 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Jushi Holdings Inc. stock logo
JUSHF
Jushi
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
5.63
5.63
Jushi Holdings Inc. stock logo
JUSHF
Jushi
N/A
1.02
0.48
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
9.33
9.33
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
9.34
9.34

Institutional Ownership

CompanyInstitutional Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Jushi Holdings Inc. stock logo
JUSHF
Jushi
21.68%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
Jushi Holdings Inc. stock logo
JUSHF
Jushi
22.48%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5397.99 million94.36 millionOptionable
Jushi Holdings Inc. stock logo
JUSHF
Jushi
1,234196.70 million152.48 millionNot Optionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.13 million22.85 millionNot Optionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.87 million76.39 millionOptionable

Recent News About These Companies

Q3 EPS Forecast for Solid Biosciences Increased by Analyst
Leerink Partnrs Weighs in on SLDB Q1 Earnings
HC Wainwright Brokers Reduce Earnings Estimates for SLDB

New MarketBeat Followers Over Time

Media Sentiment Over Time

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$5.35 +0.40 (+8.08%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$5.38 +0.03 (+0.47%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Jushi stock logo

Jushi OTCMKTS:JUSHF

$0.67 +0.01 (+1.58%)
As of 08/22/2025 03:59 PM Eastern

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$18.71 +0.31 (+1.68%)
Closing price 08/22/2025 03:54 PM Eastern
Extended Trading
$18.71 0.00 (0.00%)
As of 08/22/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.93 +0.27 (+4.77%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$5.90 -0.03 (-0.57%)
As of 08/22/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.